Table 4.
Health-related quality of life compared between patients with inflammatory bowel diseases and healthy controls.
| HRQoL measurement (mean ± SD) | IBD patients | Healthy control | Unadjusted | Adjusteda | ||
|---|---|---|---|---|---|---|
| Mean differences (95% CI) | P | Mean differences (95% CI) | P | |||
| Active disease (n; IBD = 101, control = 101) | ||||||
| SIBDQb | 50.8 ± 13.7 | 63.2 ± 5.1 | 12.3 (9.5–15.2) | <.01 | 12.4(9.5–15.2) | <.01 |
| HADS-anxietyc | 4.9 ± 4.5 | 3.3 ± 2.5 | 1.6 (0.6–2.7) | <.01 | 1.7 (0.7–2.8) | <.01 |
| HADS-depressionc | 3.8 ± 3.2 | 2.2 ± 2.2 | 1.6 (0.8–2.4) | <.01 | 1.7 (0.9–2.5) | <.01 |
| FACIT-Fatigueb | 39.2 ± 9.4 | 45.9 ± 4.1 | 6.7 (4.7–8.8) | <.01 | 6.8 (4.8–8.8) | <.01 |
| Work productivity impairment %c | 25.0 ± 27.9 | 4.7 ± 7.7 | 20.3 (13.0–27.7) | <.01 | 21.1 (13.9–28.3) | <.01 |
| EQ5D5L-TTOb | 0.871 ± 0.218 | 0.960 ± 0.064 | 0.089 (0.045–0.134) | <.01 | 0.096 (0.052–0.140) | <.01 |
| EQ5D5L-VASb | 84.0 ± 16.5 | 88.1 ± 9.5 | 15.6 (11.7–19.6) | <.01 | 16.3 (12.4–20.1) | <.01 |
| Clinical remission (n; IBD = 108, control = 108) | ||||||
| SIBDQb | 58.8 ± 12.3 | 62.8 ± 4.9 | 3.9 (1.4–6.5) | <.01 | 3.7 (1.1–6.2) | <.01 |
| HADS-anxietyc | 3.1 ± 3.3 | 3.5 ± 2.4 | 0.4 (–0.4 to 1.1) | .35 | 0.4 (–0.4 to 1.1) | .34 |
| HADS-depressionc | 3.0 ± 2.9 | 2.5 ± 2.5 | 0.5 (–1.2 to 0.2) | .16 | 0.5 (–1.2 to 0.2) | .16 |
| FACIT-Fatigueb | 42.5 ± 7.2 | 45.3 ± 4.4 | 2.8 (1.2–4.4) | <.01 | 2.7 (1.0–4.3) | <.01 |
| Work productivity impairment %c | 10.0 ± 19.7 | 8.5 ± 12.8 | 1.5 (–7.2 to 4.3) | .61 | 1.5 (–7.2 to 4.2) | .61 |
| EQ5D5L-TTOb | 0.955 ± 0.074 | 0.967 ± 0.048 | 0.012 (–0.004 to 0.029) | .16 | 0.012 (–0.005 to 0.029) | .16 |
| EQ5D5L-VASb | 83.1 ± 14.2 | 87.9 ± 8.2 | 4.8 (1.5–8.1) | <.01 | 3.9 (0.5–7.2) | .02 |
| Steroid-free clinical remission (n; IBD = 78, control = 78) | ||||||
| SIBDQb | 59.8 ± 11.3 | 63.3 ± 4.5 | 3.4 (0.7–6.1) | <.01 | 3.1 (0.4–5.8) | .03 |
| HADS-anxietyc | 2.7 ± 2.6 | 3.4 ± 2.5 | 0.7 (–1.4 to 0.1) | .11 | 0.6 (–1.5 to 0.2) | .12 |
| HADS-depressionc | 2.8 ± 2.7 | 2.6 ± 2.5 | 0.5 (–0.6 to 1.1) | .58 | 0.4 (–0.5 to 1.1) | .47 |
| FACIT-Fatigueb | 42.8 ± 6.5 | 45.3 ± 4.3 | 2.5 (0.8–4.3) | <.01 | 2.3 (0.5–4.0) | .01 |
| Work productivity impairment %c | 12.0 ± 21.6 | 6.9 ± 11.0 | 5.1 (–1.7 to 11.8) | .14 | 4.8 (–1.8 to 11.3) | .15 |
| EQ5D5L-TTOb | 0.957 ± 0.065 | 0.971 ± 0.037 | 0.014 (–0.031 to 0.003) | .12 | 0.015 (–0.032 to 0.002) | .08 |
| EQ5D5L-VASb | 83.9 ± 13.6 | 87.9 ± 8.2 | 3.9 (0.1–7.8) | .48 | 3.0 (0.9–6.9) | .13 |
Abbreviations: SIBDQ: Short Inflammatory Bowel Disease Questionnaire; FACIT-F: Functional Assessment of Chronic Illness Therapy-Fatigue, Percentage of Work oductivity Impairment questionnaire; EQ5D5L-TTO and VAS: European Quality of Life 5-Dimensions 3-Level, time-trade-off and visual analog scale; HADS: Hospital Anxiety and Depression Scale.
Adjusted for marriage status and educational level.
Higher values for SIBDQ, FACIT-F, EQ5D5L scores indicate good quality of life.
Higher values for WPAI, HADS scores indicate poor quality of life.